Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.

Back to Pharmaceutical Executive · Report a problem